ArticleMethods in molecular biology (Clifton, N.J.)2025
Design and Evaluation of a Truncated Protein Induction Strategy by Antisense Oligonucleotide-Mediated Exon Skipping.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense oligonucleotide (ASO)-mediated exon skipping is an effective method for generating truncated proteins by altering mRNA splicing. This technique, enabling in situ truncation of proteins, provides a rapid way to investigate the functions of specific domains encoded by the targeted exon(s). In this methodological chapter, we focus on the mouse transcription factor ARID3A (AT-rich interactive domain 3A), which contains a DNA-binding domain (ARID domain) and a nuclear matrix-binding domain (Rekles Beta domain). We describe the design of an ASO targeting the donor splice site of Arid3a exon 8, which primarily encodes the Rekles beta domain, to generate a truncated protein lacking nuclear matrix-binding capacity while preserving an open reading frame. The ASO is specifically designed to hybridize only with Arid3a pre-mRNA, thus minimizing off-target effects. The effect of the ASO is evaluated first by RT-PCR to measure the proportion of alternative transcripts with skipped exon. Alternative transcripts can be subsequently characterized by Sanger sequencing. RT-qPCR is then performed outside the targeted exon to ensure that the overall transcription of the gene is unaffected and to exclude RNA degradation. Finally, protein analysis techniques, such as cellular imaging using immunofluorescence labeling, are used to assess the production of the truncated protein. This ASO-mediated exon skipping approach provides a reliable method for exploring the functional importance of specific protein domains.
Indexed as
Identifiers
40699429What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.